The N-terminal domain of the non-receptor tyrosine kinase ABL confers protein instability and suppresses tumorigenesis
Open Access
- 1 July 2020
- journal article
- research article
- Published by Elsevier BV in Online Journal of Public Health Informatics
- Vol. 295 (27), 9069-9075
- https://doi.org/10.1074/jbc.ra120.012821
Abstract
No abstract availableFunding Information
- Cancer Prevention and Research Institute of Texas (RP180769)
- The National Natural Science Foundation of China (31671476)
This publication has 24 references indexed in Scilit:
- Role of ABL family kinases in cancer: from leukaemia to solid tumoursNature Reviews Cancer, 2013
- Pushing the limits of targeted therapy in chronic myeloid leukaemiaNature Reviews Cancer, 2012
- Activation of Abl Family Kinases in Solid TumorsGenes & Cancer, 2012
- Molecular Pathways: BCR-ABLClinical Cancer Research, 2012
- The impact of translocations and gene fusions on cancer causationNature Reviews Cancer, 2007
- Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell lineCell Death & Differentiation, 2005
- The BCR-ABL Story: Bench to Bedside and BackAnnual Review of Immunology, 2004
- Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradationProceedings of the National Academy of Sciences of the United States of America, 2001
- BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent mannerCell, 1991
- CHROMOSOME CHANGES IN HUMAN LEUKEMIA AND A TENTATIVE ASSESSMENT OF THEIR SIGNIFICANCEAnnals of the New York Academy of Sciences, 1964